Last reviewed · How we verify
LPX-TI641
LPX-TI641 is a Small molecule drug developed by LAPIX Therapeutics Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | LPX-TI641 |
|---|---|
| Sponsor | LAPIX Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis (PHASE1)
- Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis (PHASE1)
- First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LPX-TI641 CI brief — competitive landscape report
- LPX-TI641 updates RSS · CI watch RSS
- LAPIX Therapeutics Inc. portfolio CI
Frequently asked questions about LPX-TI641
What is LPX-TI641?
LPX-TI641 is a Small molecule drug developed by LAPIX Therapeutics Inc..
Who makes LPX-TI641?
LPX-TI641 is developed by LAPIX Therapeutics Inc. (see full LAPIX Therapeutics Inc. pipeline at /company/lapix-therapeutics-inc).
What development phase is LPX-TI641 in?
LPX-TI641 is in Phase 1.
Related
- Manufacturer: LAPIX Therapeutics Inc. — full pipeline
- Compare: LPX-TI641 vs similar drugs
- Pricing: LPX-TI641 cost, discount & access